Abstract
Live mammalian cells are equipped with a synthetic cell invasion system that enables their target‐specific insertion into other live mammalian cells. By conjugating RhoA activator to a transmembrane protein that is segregated from cell–cell interface when specific cell contact occurs, polarization of RhoA activity is synthetically induced inside the cells in response to specific cell contact. This polarization is a sufficient condition for invader cells to selectively penetrate cells expressing a target antigen. Further, when an acid‐responsive fusogenic protein is expressed on invader cells, invader/receiver cell fusion occurs after invasion, and the invader's intracellular contents are released into the recipient's cytosol. It is shown that this system can be used for specific cell ablation. This synthetic‐biology‐inspired cell invasion/fusion system might open the door to using whole mammalian cells for cargo delivery purposes or for ablation of a specific cell type.
Keywords: biotechnology, cell contacts, cell fusion, cell invasion, synthetic biology
In the process of entosis or emperipolesis, a whole living cell invades another living cell.1, 2 This process is different from endocytosis, in that the cells that are eventually engulfed actively invade the recipient cells. A system that could force cells to invade a specific class of other cells would be an attractive tool for biotechnological use, because, for example, it might allow mammalian cells to be used to deliver a variety of cargoes into target cells. Although synthetic phagocytosis of target cells has been reported,3 synthetic cell invasion has not been described. Thus, we set out to develop a synthetic system that would furnish live whole cells with the ability to achieve target‐cell‐specific invasion.
Natural cell invasion is reported to require polarized actin dynamics in the invader cells.4, 5 More concretely, in an invader cell, RhoA deactivator (e.g., a GTPase‐activating protein for Rho, p190A RhoGAP) accumulates at the cell–cell interface with a receiver cell,5 and RhoA activator (e.g., a guanine nucleotide exchange factor (GEF) for Rho, PDZ‐RhoGEF) accumulates at the rear side of the invader cell.4 We hypothesized that this polarization of RhoA activity, inside the invader‐cell‐to‐be, is sufficient to cause cell invasion, and thought about how to synthetically induce this polarization in response to specific cell contact. For this purpose, we focused on biophysical movement of a transmembrane protein, CD43EX‐45INT (chimeric protein of extracellular and transmembrane domain of CD43 and intracellular domain of CD45). This protein expressed on a mammalian cell bearing an antigen‐recognizing receptor with surface‐displayed single chain antibody (scFv) is reported to be segregated from the cell‐cell interface when the cell binds to some other cells via scFv‐target antigen interaction,6, 7 while the antigen‐recognizing receptor accumulates at the cell‐cell interface. We hypothesized that we could synthetically cause the polarization of RhoA activity by replacing the intracellular domain of CD43ex‐45int with RhoA in an active form, and the intracellular domain of the antigen‐recognizing receptor with a dominant‐negative form of RhoA (Figure 1 a).
We first prepared a plasmid encoding CD43, whose intracellular domain was replaced with yellow fluorescent protein (CD43EX‐YFP), and a chimeric receptor bearing an extracellular antigen recognition site (model antigen: a well‐known breast cancer marker, human epidermal growth factor receptor 2 (HER2); single‐chain variable fragment (scFv) against HER2: ML398), the transmembrane domain from CD28, and intracellular cyan fluorescent protein (ML39‐CD28TM‐CFP). HEK‐293 cells were transfected with these constructs, and were mixed with model target (HEK‐HER2‐iRFP) or nontarget (HEK‐iRFP) cells. Then, the localization of YFP and CFP was observed. As a result, YFP was segregated from the cell–cell interface, while CFP accumulated at the interface only when the cells were mixed with target cells. This result confirms that intracellular part of CD43 can be exchanged without the loss of segregation ability from the cell‐target cell interface that is formed by interaction of target antigen and the newly developed antigen recognition receptor. It was indicated that replacing YFP and CFP directly with active RhoA and dominant‐negative RhoA, respectively, would initiate the desired polarization of RhoA activity (Figure S1a, Supporting Information).
Therefore, we next replaced the intracellular part of CD43 with constitutively active RhoA (RhoACA), in which the CAAX domain is deleted (ΔCAAX) to avoid redundancy of membrane‐localizing domain, and coexpressed it with the antigen recognition receptor whose intracellular part was replaced with dominant‐negative RhoA (RhoADN (ΔCAAX)) in HEK‐293 cells. In this setting, we expected that the desired polarization of RhoA signaling activity (i.e., higher RhoA activity at the rear side of an invader cell and lower RhoA activity at the interface with the receiver cell) would occur only when the cells become attached to target cells (Figure 1a). Indeed, only when the engineered cells bearing correct RhoA polarization were mixed with target HEK‐HER2‐iRFP cells did we observe cell‐in‐cell structure (Figure 1b,c; for larger‐scale images, see Figure S2 in the Supporting Information). It is noteworthy that the engineered cells invaded only the target cells even in mixed cultures of target and nontarget cells (Figure S3, Supporting Information). These results indicate that it would be possible to use the invader cells as target‐specific delivery vesicles.
Next, we focused on releasing the intracellular contents of invader cells into the cytosol of receiver cells, in order to explore the possibility of delivering various functional molecules into the receiver cells. However, in the process of entosis or emperipolesis, most invader cells are eventually killed by the receiver cells through lysosomal digestion, and some cells even escape from the receiver cells.1 We found that cells that were forced to invade target cells by the synthetic cell invasion system met the same fate (Figure S4, Supporting Information). Therefore, to achieve release of the intracellular contents, we expressed a fusogenic protein VSV‐G, which promotes cell fusion under acidic conditions,9 on the invader cells, because we thought that the environment of the invader cells after invasion would become acidic due to the initiation of lysosomal digestion of invader cells by the recipient cells (Figure 2 a). We found that VSV‐G induced membrane fusion after the invasion, and the intracellular contents of the invader cells were completely released into the cytosol of receiver cells as we had hoped (Figure 2b). We investigated the effect of invader: receiver ratio on invasion/fusion efficacy, and found that invasion/fusion occurs with increasing probability (reaching ≈80%) as the invader cell ratio is increased, indicating that this invasion/fusion system is robust, at least in the current setting (Figure 2c,d and Figure S5, Supporting Information). Also, we confirmed this cell invasion/fusion remained target‐specific even in mixed cultures of target and nontarget cells (Figure S6, Supporting Information).
The success of this invasion‐triggered cell‐fusion system allowed us to construct a semiquantitative system for evaluation of cell invasion that has higher throughput than observation under a microscope. This evaluation system was designed such that when invasion/fusion occurs, a synthetic transcription factor tetracycline‐dependent transactivator (tTA) transfected into the invader cells and its reporter transfected into the receiver cells encounter each other, leading to expression of the reporter gene secreted alkaline phosphatase (SEAP) (Figure 2a). Using this evaluation system, we confirmed increased reporter gene expression from target receiver cells mixed with engineered cells bearing both invasion and fusion components (Figure 2e; see Figure S7 and Note S1 of the Supporting Information for comparison of suspension and monolayer cultures). This result demonstrates that the invasion system worked well, without the need for subjective judgment of cell‐in‐cell structure, and directly shows that cells equipped with the invasion/fusion system can target‐specifically deliver functional protein into receiver cells. With this system, we also found that the indispensable part of this synthetic invasion system was activation of RhoA at the rear side of the cells rather than repression of RhoA at the cell–cell interface (Figure S8, Supporting Information). (However, as the invasion efficiency did not change so much, we continued to use the antigen recognition receptor with RhoADN in further studies.) Further, we confirmed that the system also works efficiently with a physiologically more relevant RhoA activator, RhoGEF (catalytic domain of p63RhoGEF10), as an effector (Figure S8, Supporting Information). Additionally, the system worked with DARPin11 (designed ankyrin repeat proteins; a genetically engineered antibody‐mimetic derived from ankyrin proteins) as an alternative to the antigen recognition moiety, and PDGFR transmembrane domain as a moiety to express the receptor on the cell membrane (Figure S8, Supporting Information and see Figure S1b of the Supporting Information for confirmation of protein segregation with antigen‐recognizing receptor bearing PDGFR transmembrane domain). These results indicate considerable design flexibility of the invasion components. Importantly, this synthetic invasion/fusion system was portable between different invader cell lines (we examined HEK‐293T cells, immobilized human mesenchymal stem cells (hMSC‐TERT), and Hela cells) (Figure S9, Supporting Information), providing further support for the novel finding that RhoA polarization in the invader cell is a sufficient condition for cell invasion to occur.
Next, we assessed the fate of the fused cells after invasion. We expressed a firefly luciferase and tTA‐specific PTET (tetracycline‐responsive promoter)‐driven red‐fluorescent‐protein (dsRed) expression cassette in the receiver cells, and a constitutive tTA expression unit in the invader cells, which allowed sorting of the fused dsRed‐positive cells followed by a proliferation assay utilizing firefly luminescence (Figure 3 a). Microscopic analysis and luminescence assay after sorting revealed that most of the fused cells (dsRed+) retained the capacity for protein expression for a while with the two separate nuclei, but did not divide and eventually died within about 10 days (Figure 3b and Figure S10, Supporting Information). The slow increase of the luminescence signal in the dsRed+ population (Figure 3b) was thought to be due to contamination with nonfused cells (fluorescence activated cell sorting (FACS) efficacy did not reach 100%).
Therefore, we next examined whether the target‐specific cell invasion/fusion system could be used for specific cell ablation. For proof of concept, we prepared model target and nontarget cells stably expressing firefly luciferase (HEK‐HER2‐iRFP‐Luc‐ZsGreen and HEK‐iRFP‐Luc‐ZsGreen, respectively), and mixed them with designed invader cells (Figure 3c). The invader/receiver ratio was set at 11 to increase cell killing efficacy in Figure 3c, and the effect of the invader/receiver ratio on cell killing efficiency is shown in Figure S11 (Supporting Information). (Note that the “invader cells” were not presorted, and so included cells that had not taken up plasmids.) Even without cell sorting after invasion/fusion, we observed clear suppression of the proliferation of only the target cells (Figure 3d,e). This result indicates that designer cells equipped with the target‐specific invasion/fusion system can be used for specific cell ablation.
In summary, we have developed a novel synthetic‐biology‐inspired system that can force mammalian cells to invade specific target cells. We believe it will be possible with this system to use the invader cells as delivery vesicles for various cargo molecules, including proteins and small molecules. This cell‐based delivery system might have advantages over other vesicle‐based delivery systems, because it should be possible to exploit the inherent cell migration properties of certain cell types, such as the tumor tropism of mesenchymal stem cells.12 Further, when VSV‐G is coexpressed, the invader cells fuse with the receiver cells after invasion, releasing their whole intracellular contents into the cytosol of the receiver cells. We also showed that this target‐cell‐specific invasion/fusion system is potentially available for specific cell ablation. Because the fused cells remained alive for certain length of time and the protein delivered by invader cells was functional in the fused cells, it might be possible to force the fused cells to exert additional functions that result in a potent bystander effect (for example, expression of a toxic protein to kill surrounding cancer cells),7, 13 which is not feasible with other cancer ablation methods.
From the viewpoint of future clinical applications, it will be necessary to create invader cells stably equipped with invasion/fusion components. In this context, we confirmed that expression of the invasion components did not kill the invader cells on the time scale of transient transfection (Figure S12, Supporting Information). In addition, cells stably expressing RhoA have been reported,14 so it could be possible to construct stable invader cells. However, stable expression of VSV‐G is reported to be toxic for cells,15 so further work will be needed to establish that the present proof‐of‐concept study can be translated into practical applications. A promising strategy could be to engineer the invasion/fusion components under the control of specific‐cell‐contact‐sensing transgene expression devices.7, 16 If we wish to use the invasion/fusion system for pure delivery purposes, the fact that the fused cells did not proliferate normally is problematic. However, it may be worth trying to use enucleated cells as invader cells to overcome this issue (this system would work in enucleated cells, since it does not require transcription/translation steps), because it is possible that the presence of multiple nuclei in one cell, an unusual situation for the cell, may be the reason why proliferation stopped. Further study of these issues, as well as investigation of the generalizability of the target and the in vivo behavior of the invader cells will be necessary for future applications.
Nevertheless, we believe that this first‐in‐class synthetic target‐cell‐specific invasion/fusion system is biologically very interesting, and might open the door to using engineered mammalian cells as “Trojan horses” for killing or delivering various molecules to specific target cells.
Conflict of Interest
The authors declare no conflict of interest.
Supporting information
Acknowledgements
The authors thank D. Bojar, M. Xie, T. Inoue, and addgene construct suppliers (see the Supporting Information) for providing plasmids, T. Horn and E. Montani for help with microscopy, T. Lopes and V. Jäggin for help with FACS experiments, and Y. Urano for permission to use certain laboratory equipment for this study. This work was supported by the European Research Council (ERC) advanced grant (ProNet, no. 321381) and in part by the National Centre of Competence in Research (NCCR) for Molecular Systems Engineering. R. Kojima was supported by a postdoctoral fellowship by the Human Frontier Science Program (HFSP).
Kojima R., Fussenegger M., Adv. Sci. 2018, 5, 1700971 10.1002/advs.201700971
References
- 1. Krishna S., Overholtzer M., Cell. Mol. Life Sci. 2016, 73, 2379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.a) Overholtzer M., Brugge J. S., Nat. Rev. Mol. Cell Biol. 2008, 9, 796; [DOI] [PubMed] [Google Scholar]; b) Overholtzer M., Mailleux A. A., Mouneimne G., Normand G., Schnitt S. J., King R. W., Cibas E. S., Brugge J. S., Cell 2007, 131, 966; [DOI] [PubMed] [Google Scholar]; c) Xia P., Wang S., Guo Z., Yao X., Cell Res. 2008, 18, 705. [DOI] [PubMed] [Google Scholar]
- 3. Onuma H., Komatsu T., Arita M., Hanaoka K., Ueno T., Terai T., Nagano T., Inoue T., Sci. Signal. 2014, 7, rs4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Purvanov V., Holst M., Khan J., Baarlink C., Grosse R., eLife 2014, 3, e02876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Sun Q., Cibas E. S., Huang H., Hodgson L., Overholtzer M., Cell Res. 2014, 24, 1288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.a) Irles C., Symons A., Michel F., Bakker T. R., van der Merwe P. A., Acuto O., Nat. Immunol. 2003, 4, 189; [DOI] [PubMed] [Google Scholar]; b) James J. R., Vale R. D., Nature 2012, 487, 64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Kojima R., Scheller L., Fussenegger M., Nat. Chem. Biol. 2018, 14, 42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Song E., Zhu P., Lee S. K., Chowdhury D., Kussman S., Dykxhoorn D. M., Feng Y., Palliser D., Weiner D. B., Shankar P., Marasco W. A., Lieberman J., Nat. Biotechnol. 2005, 23, 709. [DOI] [PubMed] [Google Scholar]
- 9. Nagaraj S., Mills E., Wong S. S. C., Truong K., ACS Synth. Biol. 2013, 2, 173. [DOI] [PubMed] [Google Scholar]
- 10. Van Unen J., Reinhard N. R., Yin T. F., Wu Y. I., Postma M., Gadella T. W. J., Goedhart J., Sci. Rep. 2015, 5, 14693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Pluckthun A., Annu. Rev. Pharmacol. Toxicol. 2015, 55, 489. [DOI] [PubMed] [Google Scholar]
- 12.a) Hagenhoff A., Bruns C. J., Zhao Y., von Luttichau I., Niess H., Spitzweg C., Nelson P. J., Expert Opin. Biol. Ther. 2016, 16, 1079; [DOI] [PubMed] [Google Scholar]; b) Ramdasi S., Sarang S., Viswanathan C., Int. J. Hematol. Oncol. Stem Cell Res. 2015, 9, 95. [PMC free article] [PubMed] [Google Scholar]
- 13.a) Christensen C. L., Gjetting T., Poulsen T. T., Cramer F., Roth J. A., Poulsen H. S., Clin. Cancer Res. 2010, 16, 2308. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Link N., Aubel C., Kelm J. M., Marty R. R., Greber D., Djonov V., Bourhis J., Weber W., Fussenegger M., Nucleic Acids Res. 2006, 34, e16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Horiuchi A., Kikuchi N., Osada R., Wang C., Hayashi A., Nikaido T., Konishi I., Cancer Sci. 2008, 99, 2532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Sanber K. S., Knight S. B., Stephen S. L., Bailey R., Escors D., Minshull J., Santilli G., Thrasher A. J., Collins M. K., Takeuchi Y., Sci. Rep. 2015, 5, 9021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Morsut L., Roybal K. T., Xiong X., Gordley R. M., Coyle S. M., Thomson M., Lim W. A., Cell 2016, 164, 780. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.